


Stockholm; March 22, 2010



*“We seek to increase the number of successful
Organ Transplantations, save lives through rapid
diagnosis of Severe Sepsis and introduce a more
specific treatment of Rheumatoid Arthritis*

Business idea



***"We develop protein
pharmaceuticals and diagnostic
methods"***

Focus:

- ***inflammation***
- ***pre-clinical/early clinical development***

A quick glance



» *Founded 2001*

» *At NASDAQ OMX First North since 2007*

» *Market cap: approximately SEK 35 M*

» *Based in Lund, seven employees*

» *Collaboration with five medical professors
at Karolinska Institute, Lund University and
Skåne University Hospital*

Share holders:

Bo Håkansson

38,5%

Mikael Lönn

18,4%

Product candidates & partners

anti-alpha-11

*Treatment of Rheumatoid
Arthritis (RA)*



HMD-301

*Diagnosis of Severe
Sepsis*




IdeS

Organ Transplantation

Partnership discussions ongoing

anti-alpha-11



» *Synovial Fibroblast: a key player in RA*

» *High levels of alpha-11 in cartilage of RA-patients*

» *Antibodies against alpha-11 has better treatment effect than Enbrel in RA-models*

» *anti-alpha-11 treatment acts locally in the joint*

» *RA biologicals market estimate: 12 billion USD*

The biotech business model



MAXY-4

- » *Maxygen Inc & Astellas in 2008*
- » *In preclinical development at agreement*
- » *10+ 160 million USD + double digit royalties*

T-5254

- » *Toyama Chemical & Roche during 2007*
- » *In phase I at agreement*
- » *Up-front and milestones totaling 370 million USD + royalties*

anti-alpha-11 partnership



» *Candidate Drug (CD) generation at subsidiary Biosite Discovery*

» *Milestones to Hansa Medical at CD selection*

» *50/50 cost/revenue sharing after CD selection*

Partnership goal:

Out-license in late preclinical or early clinical phase to Big Pharma/Big Biotech

HMD-301 Diagnosis of severe sepsis



A simple blood test at:

- » *Intensive Care Unit*
- » *Emergency Department*
- » *Infectious Disease Clinic*
- » *Post-surgery Ward*

...identifies individuals at high risk of developing severe sepsis

HMD-301 quantifies level of HBP in blood

Partnership with Axis – Shield



» Axis-Shield and Hansa Medical develops the product towards market introduction 2011/2012

» Market estimate: 3 million analyses per year and 90 million USD in sales

» Milestones and royalties to Hansa Medical

» All development costs taken by Axis-Shield since June 2009

IdeS - Sensitized patients



Sensitized kidney transplantation patients

» *High levels of anti-donor antibodies*


» *In dialysis for many years*

» *Approx. 5000 patients annually (orphan drug)*

Development stages & goals



IdeS
Organ Transplantation



RESEARCH

**PROOF OF
CONCEPT**

**PRECLINICAL
DEVELOPMENT**

PHASE I

PHASE II

At present 

Latest news

INBJUDAN TILL TECKNING AV AKTIER I
HANSA MEDICAL AB (PUBL) – MARS 2010



hansa
medical

» Rights issue with preferential rights to present shareholders

» Will bring SEK 27 M to the company

» For anti-alpha-11 lead candidate generation and GMP production of IdeS

» Three major share holders will subscribe their pro rata shares

» Fully secured